Search research articles
Contact Us
Filters
Showing results (81-90 of 151) with videos related to
Page
of 16
Sort By:
Annals of Surgery
|
March 17, 1999
Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer
A M Lowy, P F Mansfield, S D Leach, et al.
Anticancer Research
|
January 1, 1981
Neuroendocrine small cell carcinomas in miscellaneous primary sites: implications for staging and therapy
R Pazdur, P Bonomi, V E Gould, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 1997
Neurotoxicity of CI-980, a novel mitotic inhibitor
C A Meyers, A P Kudelka, C A Conrad, et al.
Investigational New Drugs
|
November 1, 1991
Phase I trial of FK973: description of a delayed vascular leak syndrome
R Pazdur, D H Ho, K Daugherty, et al.
Oncology Nursing Forum
|
January 1, 1991
5-Fluorouracil and recombinant interferon alfa-2a: review of activity and toxicity in advanced colorectal carcinomas
R Pazdur, D Jackson, B Shepherd, et al.
American Journal of Clinical Oncology
|
December 10, 1997
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity
R Pazdur, C Meyers, E Diaz-Canton, et al.
American Journal of Clinical Oncology
|
December 1, 1996
Phase II study of ZD1694 in patients with advanced gastric cancer
N J Meropol, R Pazdur, M Vincent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 1998
Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil
D H Ho, R Pazdur, W Covington, et al.
Cancer Research
|
August 1, 1988
Acodazole hydrochloride: phase I trial, pharmacokinetics, and evaluation of cardiotoxicity in dogs
R Pazdur, G G Chabot, C A Campbell, et al.
Anti-Cancer Drugs
|
January 12, 2000
Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors
R A Newman, J Kim, B M Newman, et al.
Page
of 16
Search research articles
Search
Showing results (81-90 of 151) with videos related to
Sort By:
Page
of 16
Annals of Surgery
|
March 17, 1999
Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer
A M Lowy, P F Mansfield, S D Leach, et al.
Anticancer Research
|
January 1, 1981
Neuroendocrine small cell carcinomas in miscellaneous primary sites: implications for staging and therapy
R Pazdur, P Bonomi, V E Gould, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 1997
Neurotoxicity of CI-980, a novel mitotic inhibitor
C A Meyers, A P Kudelka, C A Conrad, et al.
Investigational New Drugs
|
November 1, 1991
Phase I trial of FK973: description of a delayed vascular leak syndrome
R Pazdur, D H Ho, K Daugherty, et al.
Oncology Nursing Forum
|
January 1, 1991
5-Fluorouracil and recombinant interferon alfa-2a: review of activity and toxicity in advanced colorectal carcinomas
R Pazdur, D Jackson, B Shepherd, et al.
American Journal of Clinical Oncology
|
December 10, 1997
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity
R Pazdur, C Meyers, E Diaz-Canton, et al.
American Journal of Clinical Oncology
|
December 1, 1996
Phase II study of ZD1694 in patients with advanced gastric cancer
N J Meropol, R Pazdur, M Vincent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 1998
Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil
D H Ho, R Pazdur, W Covington, et al.
Cancer Research
|
August 1, 1988
Acodazole hydrochloride: phase I trial, pharmacokinetics, and evaluation of cardiotoxicity in dogs
R Pazdur, G G Chabot, C A Campbell, et al.
Anti-Cancer Drugs
|
January 12, 2000
Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors
R A Newman, J Kim, B M Newman, et al.
Page
of 16